INTRODUCTION
Brown adipose tissue is specialized in non-shivering thermogenesis in small mammals and is responsible for heat production associated with the expression of the mitochondrial uncoupling protein 1 ('UCP-1'). Since fatty acids are thermogenic fuels, this tissue also performs lipid synthesis. It is well known that insulin regulates lipogenesis and glucose is an essential lipogenic substrate. Moreover, glucose transport is maintained mainly by the activity of the insulin-regulated glucose transporter GLUT4 in this tissue [1] . Foetal brown adipocytes display high-affinity binding sites for both insulin and insulin-like growth factor I ('IGF-I'), and both signals induce GLUT4 mRNA expression concomitant with the onset of adipogenic-and thermogenic-differentiation programs [2] [3] [4] .
In principle, there are at least three mechanisms by which insulin could modulate GLUT4 function contributing to increased glucose uptake in peripheral tissues, including brown adipocytes. First, insulin could promote translocation of pre-existing intracellular sequestered populations of GLUT4 proteins to the cell surface. Secondly, insulin could alter the intrinsic transport activity of GLUT4 proteins at the cell surface by direct modifications of GLUT4 itself or by interaction with other regulatory molecules. Thirdly, insulin could up-regulate the amount of GLUT4 protein by increased biosynthesis, decreased degradation or both. Although these mechanisms are not mutually exclusive, the first model has been the most intensively studied; the participation of phosphoinositide 3-kinase (PI 3-kinase), Akt/protein kinase B ('PKB') and several protein kinase C isoforms in insulin-induced GLUT4 redistribution to the plasma membrane in adipocytes and myocytes is well established [5] [6] [7] [8] [9] [10] [11] . Regarding the second model, a potential role for p38 mitogenactivated protein kinase ('MAP kinase') in the activation of Abbreviations used: CAT, chloramphenicol acetyltransferase; C/EBP, CCAAT/enhancer-binding protein; MEF, myocyte enhancer factor; FAS, fatty acid synthase; FCS, foetal calf serum; MEM, minimal essential medium with Earle's salts; β-gal, β-galactosidase; SREBP1, sterol-regulatory-element-binding protein 1. 1 Both authors contributed equally to the experimental work. 2 To whom correspondence should be addressed (e-mail: mlorenzo@farm.ucm.es).
GLUT4 transporter by insulin has been proposed in some cellular systems [12] . However, the mechanism by which insulin could contribute to glucose uptake through regulation of GLUT4 gene expression remains largely unexplored. The expression of GLUT4 is subject to tissue-specific, hormonal and metabolic regulation [5, 13] . Studies in vivo clearly indicate that GLUT4 gene expression is down-regulated in states of relative insulin deficiency such as streptozotocin-induced diabetes and chronic fasting, a situation that is reversed by insulin treatment and refeeding [14] [15] [16] . However, in vitro studies failed to establish a stimulatory role of insulin on GLUT4 expression in white adipocytes and skeletal muscle cells [17] , suggesting that additional factors could be involved in vivo. Dexamethasone, a synthetic glucocorticoid, has been shown to increase GLUT4 expression in myocytes [18] as well as to interact with insulin in GLUT4 expression in white adipocytes [19] . This prompted us to evaluate the potential role of dexamethasone as a co-regulator with insulin of glucose transporter expression using foetal rat brown adipocytes in primary culture. Our results indicate that insulin [activating myocyte enhancer factor (MEF)-2 DNA-binding activity] or dexamethasone [increasing CCAAT/enhancerbinding protein (C/EBP)-α] alone up-regulated GLUT4 mRNA and protein expression through activation of the GLUT4 promoter. A synergistic effect was observed on GLUT4 gene expression leading to a dramatic increase in glucose uptake.
MATERIALS AND METHODS

Materials
Insulin, dexamethasone and BSA (fraction V, essentially fatty acid-free) were from Sigma. The mammalian transfection kit was from Stratagene. All other reagents used were of the purest grade available. The cDNAs used as probes were GLUT4, GLUT1, C/EBPα and fatty acid synthase (FAS) [20] [21] [22] . Rabbit anti-GLUT1 and GLUT4 antibodies were supplied by Chemicon. Anti-C/EBPα (sc-61) and anti-(sterol-regulatory-element-binding protein 1) (SREBP1; sc-8984) antibodies were from Santa Cruz Biotechnology.
Cell culture
Brown adipocytes were obtained from interscapular brown adipose tissue of 20-day Wistar rat foetuses and isolated by collagenase dispersion as described previously [2] . Cells were plated at 1.5×10
6 cells/60 mm-diameter or 4×10 6 cells/100 mmdiameter tissue-culture dishes in MEM supplemented with 10 % (v/v) FCS. After 4 h of culture at 37
• C, cells were rinsed twice with PBS and 70 % of the initial cells attached to the dish forming a monolayer. Cells were then maintained for 20 h in a serum-free MEM supplemented with 0.2 % (w/v) BSA, before culture for a further 24 h in the absence or presence of various doses of dexamethasone, insulin or both.
Measurement of glucose uptake
Cells were cultured as described above and 2-deoxy-D-[1-3 H]glucose (1 µCi/ml) was added to the culture medium (MEM containing 0.2 % BSA) to a final concentration of 5 mm during the last 2 h of the culture time. Cells were then washed three times with ice-cold PBS and solubilized in 1 ml of 1 % (w/v) SDS, as described previously [23] . The radioactivity of a 200 µl aliquot was determined in a scintillation counter. In parallel dishes, proteins were determined by the Bradford method [24] , using BioRad reagent and BSA as the standard.
RNA extraction and analysis
For Northern-blot analysis of RNA, at the end of the culture time, cells were washed twice with ice-cold PBS and lysed directly with Trizol following the protocol supplied by the manufacturer for total RNA isolation [25] . Total cellular RNA (15 µg) was subjected to Northern-blot analysis, i.e. electrophoresed on 0.9 % agarose gels containing 0.66 M formaldehyde, transferred on to GeneScreen TM membranes using a VacuGene blotting apparatus (LKB-Pharmacia) and cross-linked to the membranes by UV light. Hybridization was in 0.25 mm NaHPO 4 (pH 7.2), 0.25 M NaCl, 100 µg/ml denatured salmon sperm DNA, 7 % (w/v) SDS and 50 % deionized formamide containing denatured 32 P-labelled cDNA (10 6 c.p.m./ml) for 24 h at 42 • C, as described previously [1] . cDNA labelling was carried out with [α- 32 P]dCTP to a specific activity of 10 9 c.p.m./µg of DNA by using a multiprimer DNAlabelling system kit. For serial hybridization with different probes, the blots were stripped and rehybridized subsequently as needed in each case. Membranes were subjected to autoradiography and relative densities of the hybridization signals were determined by densitometric scanning of the autoradiograms in a laser densitometer (Amersham Biosciences).
Western blotting
Cells were lysed as described previously [4] and cellular proteins or total membrane proteins (30 µg) were subjected to SDS/PAGE, transferred on to Immobilon membranes and were blocked using 5 % (w/v) non-fat dried milk in Tris-buffered saline [10 mM Tris/HCl (pH 7.5) and 150 mM NaCl], and incubated overnight with various antibodies, as indicated, in each case in Trisbuffered saline containing 0.05 % Tween-20 and 1 % (w/v) non-fat dried milk. Immunoreactive bands were visualized using the enhanced chemiluminiscence (ECL-Plus) Western blotting protocol (Amersham Biosciences).
Transfection conditions and chloramphenicol acetyltransferase (CAT) determination
The following plasmid constructs were used for transfection experiments: full-promoter GLUT4-CAT fusion gene (where the CAT reporter gene is under the control of a 2400 bp full-length 5 -flanking region of rat GLUT4 promoter, from positions −2212 to +147, relative to the transcription start site); deleted-promoter GLUT4-CAT fusion gene (a promoter with 257 bp deleted from positions −110 to +147), both were kindly provided by Dr A. Zorzano (Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain) [26] ; wild-type C/EBPα (a eukaryotic expression vector for wild-type C/EBPα) [21] ; C/EBPα (a eukaryotic expression vector for a dominantnegative mutant of C/EBPα), kindly provided by Dr A. F. Gombart (Division of Hematology, University of California, Los Angeles, CA, U.S.A.); and pCMVβ-galactosidase (β-gal) (a viral promoter-driven expression of the reporter β-gal gene).
C/EBPα harbours a point mutation at nucleotide 1063 of the C/EBPα gene (C → G substitution) that results in the amino acid substitution Arg 305 → Pro in the fork region between DNAbinding basic domain and the leucine zipper dimerization domain of the C/EBPα protein, conferring a dominant-negative property whereby the mutant polypeptide heterodimerizes with the wildtype polypeptide and prevents it from binding to DNA [27] . Primary brown adipocytes were cultured for 24 h in MEM containing 10 % (v/v) FCS and then transiently transfected using the calcium phosphate-mediated protocol with 10 µg of GLUT4-CAT fusion gene alone or combined with 10 µg of wild-type or dominant-negative C/EBPα together with 2 µg of pCMVβ-gal (to monitor transfection efficiency). After incubation for 4 h, cells were shocked with 3 ml of PBS containing 15 % (v/v) glycerol for 2 min, washed and fed with serum-free medium (either in the absence or presence of insulin and/or dexamethasone) for 24 h. Cells were then harvested and lysates were prepared for CAT and β-gal activity assays. CAT activity was determined by incubating 50 µl of cell extracts with 0.25 µCi of [ 14 C]chloramphenicol and 0.5 mM acetyl CoA in 0.25 M Tris (pH 7.8) at 37
• C for 12 h. After incubation, samples were subjected to TLC. The amount of substrate acetylated was quantified directly with a radioimaging device (Fujifilm BAS-1000). CAT enzyme activity was expressed as a percentage of [ 14 C]chloramphenicol acetylated and normalized to the internal control β-gal (assayed according to the Stratagene protocol).
Gel-shift assay
Nuclear extracts were prepared from 4×10 6 cells. Cells were resuspended at 4
• C in buffer A [10 mM Hepes/KOH (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol and 0.2 mM PMSF], allowed to swell on ice for 10 min, and then vortex-mixed for 10 s. Samples were centrifuged, and the pellet was resuspended in ice-cold buffer C [20 mM Hepes/KOH (pH 7.9), 25 % (v/v) glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM PMSF and 0.75 µg/ml each of leupeptin and aprotinin] and incubated on ice for 20 min for highsalt extraction. Cellular debris was removed by centrifugation for 2 min at 4
• C, and the supernatant fraction was stored at −70
• C. The gel mobility-shift assay was performed essentially as described previously [28] . The double-stranded oligonucleotide used as the MEF-2 probe, corresponding to the MEF-2 site in the −522/−420 enhancer from the GLUT4 promoter, was composed of the sequence 5 -CGTGGGAGCTAAAAATAGC-3 ; the double-stranded oligonucleotide used as the C/EBPα probe, corresponding to the nuclear factor-interleukin 6 ('NF-IL6') site of the cyclo-oxygenase 2 ('COX2') promoter, was 5 -GGGTATTATGCAATTGGAAG-3 . The MEF-2 and C/EBPα double-stranded oligonucleotides were chemically synthesized by Sigma (Genosys). Oligonucleotides were labelled by using Klenow polymerase and [α-
32 P]dCTP. The binding reaction was performed at 4
• C for 15 min in a buffer containing 0.5 ng of doubled-stranded oligonucleotide probe, 2 µg of poly(dIdC) and 10 µg of protein in buffer C and supplemented with 35 mM MgCl 2 . For supershift and competition assays, nuclear extracts were previously incubated for 15 min at 4
• C with 1 µl of the corresponding antibodies or 100-fold excess of unlabelled probe. DNA-protein complexes were resolved on a 6 % (w/v) polyacrylamide gel. The gel was dried and exposed to film at −70
• C.
Data analysis
Results are presented as means + − S.E.M. (n = 8 or 12) for duplicate or triplicate dishes from four independent experiments. Statistical significance was tested with a one-way ANOVA, followed by the protected least-significant different test. P < 0.01 was considered significant. In experiments using X-ray films (Hyperfim), different exposure times were used to ensure that bands were not saturated.
RESULTS
Synergistic effect of insulin and dexamethasone on GLUT4 gene expression, GLUT4 promoter activity and glucose uptake
Foetal rat brown adipocytes when isolated and maintained for 20 h in culture expressed adipogenic and thermogenic genes, such as FAS and uncoupling protein-1 ('UCP1'), whereas the expression of the insulin-regulated glucose transporter GLUT4 was barely detectable [2] . Under these conditions, treatment for 24 h with insulin up-regulated GLUT4 gene expression in a PI 3-kinase/Akt-dependent manner [4] . We have explored the effect of dexamethasone and/or insulin on GLUT4 gene expression in this cell model. Foetal rat brown adipocytes (after 4 h of attachment and cultured for 20 h in a serum-free medium) were cultured for a further 24 h in MEM containing 0.2 % BSA (with 5 mM glucose) either in the absence or presence of various doses of dexamethasone and/or insulin. The expression of GLUT4 and GLUT1 genes was studied by Northern blot, and the resulting densitometric analysis, after normalization with the amount of hybridized 18 S rRNA, are shown in Figure 1(A) . A representative experiment is depicted in Figure 1(B) . Insulin induced GLUT4 mRNA in a dose-dependent manner, producing the maximal effect (8-fold) at 10 nM, whereas dexamethasone increased basal expression of GLUT4 mRNA to the same level as insulin did (8-fold) at 100 nM. In the presence of both hormones, a synergistic effect was observed even at the lower dose of insulin (1 nM) or dexamethasone (10 nM) used, producing a maximal induction (20-fold increase) at 10 nM insulin and 100 nM dexamethasone ( Figures 1A and 1B) . These doses were used in further experiments in the present study. Regarding the expression of the ubiquitous glucose transporter GLUT1, its mRNA level remained unmodified regardless of the presence of insulin or dexamethasone ( Figure 1B) . In order to validate if the effect of dexamethasone on GLUT4 mRNA accumulation was dependent on the differentiation-inducing properties of the hormone, the expression of the adipogenic marker FAS was simultaneously analysed ( Figure 1B) . Dexamethasone did not modify the basal expression of FAS mRNA, but increased by 5-fold insulin-induced FAS gene expression. In addition to the mRNA accumulation, we studied the effect of insulin and dexamethasone treatment on GLUT4 and GLUT1 protein expression by Western-blot analysis ( Figure 1C ). Both insulin and dexamethasone alone increased GLUT4 protein content in total membrane fraction 2-fold, and treatment with the two hormones together increased the GLUT4 protein level 8-fold. No changes in GLUT1 protein content were observed under any of the treatments.
These results seem to indicate that dexamethasone and insulin are inducing transcriptional activation of GLUT4. Consequently, we decided to study the effect of both factors on the transactivation of the GLUT4 promoter driving the expression of the CAT reporter gene. After culture with MEM containing 10 % (v/v) FCS for 24 h, primary brown adipocytes were transiently cotransfected with 10 µg of full-promoter GLUT4-CAT fusion gene [rat GLUT4 full-length promoter (2400 bp)-CAT] together with 2 µg of pCMVβ-gal for internal control of transfection. After transfection, cells were cultured for 24 h in a serum-free medium in the absence or presence of 100 nM dexamethasone and/or 10 nM insulin. At the end of the culture period, cells were collected and assayed for CAT activity. A representative GLUT4-CAT TLC experiment in primary brown adipocytes is shown in Figure 2 (A). Densitometric analysis from the CAT TLC were directly counted in a phosphorimager, and values were normalized to β-gal activity. The GLUT4-CAT fusion gene was weakly transactivated in control primary brown adipocytes, whereas treatment with either 10 nM insulin or 100 nM dexamethasone resulted in a 3-fold increase, and when the two hormones were added together, the CAT activity was increased 7-fold ( Figure 2A) . These results provide evidence of a synergistic action of these hormones on GLUT4 promoter activity in a similar manner to that observed for GLUT4 mRNA and protein content.
One of the primary metabolic responses mediated by insulin is the stimulation of the facilitated glucose transport in insulinresponsive tissues such as brown adipose tissue. Since insulin and dexamethasone treatment for 24 h produced a dramatic increase in the expression of GLUT4, we decided to study glucose uptake under these experimental conditions. Glucose uptake was determined by incubation of cells in the culture medium in the presence of 2-deoxy-D- [1- 3 H]glucose during the last 2 h of culture. Parallel dishes were used for determination of protein content, since long-term treatments can affect the protein content. Results are expressed as d.p.m./µg of protein throughout 2 h of labelling ( Figure 2B ). Treatment with either insulin (10 nM) or dexamethasone (100 nM) alone for 24 h induced glucose uptake 3-fold compared with levels observed in cells maintained in the absence of hormones. The combined presence of insulin and dexamethasone dramatically increased glucose uptake 12-fold. The synergistic effect of dexamethasone and insulin on the induction of glucose uptake was found in a similar manner to the effect observed for GLUT4 promoter transactivation, mRNA and protein content. 
Transcription factors involved in up-regulation of GLUT4 gene expression by insulin and dexamethasone
The specific transcription factors involved in the transactivation of GLUT4 promoter subjected to tissue-specific, hormonal and metabolic regulation have not been totally identified yet. However, the existence of binding domains to C/EBPs has been demonstrated in the GLUT4 promoter [26] . First, we decided to study the effect of treatment of brown adipocytes with dexamethasone and/or insulin for 24 h on C/EBPα mRNA and protein expression by Northern and Western blotting as shown in Figures 3(A) and 3(B) respectively. Insulin alone slightly decreased C/EBPα expression, dexamethasone increased C/EBPα mRNA and protein accumulation 2-fold, and no further increase was observed in the presence of the two hormones. This positive effect of dexamethasone on C/EBPα protein expression, regardless of the presence of insulin, was not observed for other transcription factors determined, such as SREBP1. As a consequence, we decided to study the ability of nuclear proteins from cells cultured for 24 h in the absence or presence of dexamethasone and/or insulin to bind to a C/EBPα doublestranded oligonucleotide in gel mobility-shift experiments ( Figure  4A ). Protein binding to DNA was observed in control brown adipocytes and this binding was increased approx. 2-fold by dexamethasone treatment and 4-fold in the combined presence of dexamethasone and insulin. This band appears to be specific, since it was supershifted with the antibody against C/EBPα and disappeared in competition experiments with 100-fold molar excess of unlabelled probe. These results indicate that dexamethasone increases C/EBPα protein content and its binding to DNA and, although insulin does not induce C/EBPα expression, it is able to potentiate the activation of C/EBPα DNA-binding activity induced by dexamethasone, producing a dramatic upregulation of GLUT4 gene expression. The promoter region of the GLUT4 gene also contains a conserved binding site for the MEF-2 family of transcription factors that seems to be necessary for full promoter activity [29] . Accordingly, gel mobility-shift experiments were performed with a probe containing the MEF-2 site in the −522/−420 enhancer from the GLUT4 promoter, and nuclear extracts were obtained from cells treated as described above ( Figure 4B ). Two specific bands were detected in all the conditions, which disappeared in competition experiments with unlabelled probe. Insulin treatment doubled nuclear protein binding to DNA, regardless of the absence or presence of dexamethasone, when compared with untreated cells. These data suggest that the activation of MEF-2 could be responsible for insulin induction of GLUT4 gene expression.
Another approach to confirm the involvement of C/EBPα and MEF-2 in dexamethasone and insulin effects on GLUT4 gene expression was to perform transfection experiments with a deleted-promoter GLUT4-CAT fusion gene, which lacks the region containing these response elements (rat GLUT4 promoter of 257 bp) [13] (Figure 5A ). This GLUT4-CAT fusion gene was not transactivated in the presence of dexamethasone and/or insulin. Finally, for a more direct demonstration of the involvement of C/EBPα in the induction of GLUT4 by dexamethasone and its activation by the combined presence of insulin, we decided to use a genetic approach by using wild-type and dominant-negative C/EBPα expression vectors ( Figures 5B and 5C ). Co-transfection of a wild-type C/EBPα and full-promoter GLUT4-CAT produced a 3-fold stimulation of GLUT4-CAT fusion gene activity. Furthermore, insulin was also able to potentiate further (5-fold increase) GLUT4-CAT transactivation induced by co-transfection with C/EBPα expression vector ( Figure 5B ). Moreover, co-transfection of a dominant-negative form of C/EBPα, which prevents wild-type polypeptide binding to DNA [27] , and full-promoter GLUT4-CAT totally impaired the transactivation produced by dexamethasone and insulin treatment ( Figure 5C ).
DISCUSSION
GLUT4 expression is decreased in adipose tissue in human obesity and Type II diabetes [30] . Furthermore, adipose-selective targeting of the GLUT4 gene impaired insulin action in muscle and liver [31] , whereas a glycaemic improvement was observed in diabetic mice overexpressing GLUT4 [32] . Most studies for regulating glucose uptake in peripheral tissues have been focused on the identification of factors and pathways that improve insulin induction of GLUT4 translocation to the plasma membrane. However, insulin and/or other factors can contribute to elevation of glucose uptake by inducing the expression of GLUT4. In this regard, we have shown previously [4] that the expression of GLUT4 protein could be induced by chronic treatment with insulin. The present study demonstrates that insulin and dexamethasone produce a synergistic effect at the transcriptional level, which leads to the accumulation of GLUT4 mRNA and protein and, as a consequence, dramatically increases glucose uptake.
Dexamethasone was shown to be a potent inducer of GLUT4 gene expression in foetal brown adipocytes and this effect was accompanied by parallel stimulation of glucose uptake. The increase in GLUT4 expression produced by dexamethasone was independent of the differentiation-inducing properties of the hormone, since the expression of the adipogenic marker FAS remains unmodified. These results agreed with the positive effect of dexamethasone on GLUT4 expression observed in neonatal primary brown adipocytes [33] as well as in C2C12 muscle cells, although, in this cell line, the effect did not contribute to an increased insulin-stimulation of glucose uptake [18] . In contrast, dexamethasone failed to induce GLUT4 gene expression in 3T3-F442A adipocytes [19] . Furthermore, dexamethasone, when combined with insulin, produced a synergistic effect on both GLUT4 protein content and glucose uptake in foetal brown adipocytes in a similar fashion as described in 3T3-F442A adipocytes [19] . Moreover, dexamethasone potentiated insulininduced FAS gene expression in brown adipocytes, as shown in hepatocytes [34] .
In addition, insulin or dexamethasone induce GLUT4 gene expression at the transcriptional level, producing the transactivation of the GLUT4-CAT fusion gene transiently transfected into primary foetal brown adipocytes. Since the 2400 bp of the 5 -flanking region of the rat GLUT4 gene is devoid of sequences similar to known insulin-or glucocorticoidresponsive elements [13] , these hormones could be acting indirectly by modulating the expression of transcription factors to govern the transcription of GLUT4 gene. In this regard, the existence of C/EBPα-and MEF-2-binding domains has been described in mouse GLUT4 promoter [13] and, in fact, the hormonal effects were lost in experiments using a 257 bp GLUT4 promoter with the C/EBPα-and MEF-2-binding domains deleted. Insulin treatment resulted in the induction of MEF-2-binding activity in electrophoretic mobility gel-shift assays regardless of the absence or presence of dexamethasone. These data agree with the presence of a GLUT4-MEF-2 binding complex reported previously [29] in brown adipose tissue and indicates for the first time a positive effect of insulin on MEF-2 transcription factor in foetal brown adipocytes, a finding in agreement with the effect found in muscle from diabetic mice treated with insulin [29] . Several pieces of evidence suggest that C/EBPα could be a regulator of GLUT4 gene expression [35] , and our data demonstrate that co-transfection of primary brown adipocytes with a wild-type C/EBPα expression vector transactivates the GLUT4-CAT fusion gene in a similar fashion as dexamethasone. These results are in agreement with the reconstitution of GLUT4 gene expression observed in NIH-3T3 cells by ectopic expression of C/EBPα [36] . Furthermore, chronic dexamethasone treatment resulted in the induction of C/EBPα mRNA and protein levels in foetal brown adipocytes, in agreement with the effect observed in human preadipocytes [37] . Consequently, dexamethasone increased C/EBPα DNA-binding activity in nuclear extracts, and this effect was potentiated by the combined presence of insulin. Since insulin did not modify C/EBPα expression, the synergistic effect with dexamethasone on C/EBPα DNA-binding activity could be due to a phosphorylation event at the level of this transcription factor. In fact, insulin was able to increase further the transactivation of GLUT4 promoter produced by the C/EBPα expression vector transiently co-transfected into brown adipocytes. Furthermore, the stimulatory effect of dexamethasone and insulin on GLUT4 promoter activity was impaired when cells were co-transfected with a dominant-negative C/EBPα expression vector. In conclusion, we found individual and synergistic upregulatory effects on GLUT4 mRNA and protein content by insulin and dexamethasone, mediated by the transcription factor C/EBPα, leading to a dramatic increase in glucose uptake.
